EGFR-IN-191 

EGFR-IN-191 is an anti-tumor agent targeting both EGFR and AKT. EGFR-IN-191 exerts its anti-tumor activity by inducing DNA damage, apoptosis, cell cycle arrest, and inhibition of the PI3K/AKT-EGFR signaling pathway in tumor cells. EGFR-IN-191 can be used in the study of tumors such as triple-negative breast cancer^[1].

EGFR-IN-191 (Compound 2J) (0-20 μM; 48 h) inhibits the proliferation of MDA-MB-231, MCF-7, and Hs 578Bst cells, with IC₅₀ values of 6.89 μM, 7.79 μM, and 10.19 μM, respectively^[1].
EGFR-IN-191 (0-20 μM; 0-48 h) induces apoptosis, cell cycle arrest, DNA damage, and reduces mitochondrial membrane potential in MDA-MB-231 cells^[1].
EGFR-IN-191 (7-14.0 μM) downregulates the protein expression of EGFR, p-EGFR, and p-AKT in MDA-MB-231 cells^[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

561.62

C₃₂H₃₅NO₈

CC1=C(OC([C@H](CC2=CC=C(O)C=C2)NC(OC(C)(C)C)=O)=O)C(C)=C(O)C(C(/C=C/C3=CC=CC=C3)=O)=C1OC

Room temperature in continental US; may vary elsewhere.

Please store the product under the recommended conditions in the Certificate of Analysis.

• [1]. Chawapun P, et al. Targeting the phosphoinositide 3-kinase signaling pathway and epidermal growth factor receptor: The potential of dimethylcardamonin-derived amino acids in triple-negative breast cancer therapy. Bioorg Chem. 2026;170:109483.  [Content Brief]